Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065116 | 0.87 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3693821 | 0.84 | CYP3A4 (0.46) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8305648 | 0.84 | CYP3A4 (0.46) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL5564314 | 0.84 | CYP3A4 (0.46) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL5564319 | 0.84 | CYP3A4 (0.46) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8243274 | 0.84 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL2800499 | 0.84 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL2800497 | 0.84 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL14586229 | 0.83 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13059010 | 0.83 | ADRB3 (0.43) | ADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687459-B2 | Arylalkoxyl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687459-B2 | Arylalkoxyl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090041721-A1 | serine protease inhibitors; interferons | ENANTA PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090041721-A1 | serine protease inhibitors; interferons | ENANTA PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041721-A1 | serine protease inhibitors; interferons | PRSS1, SERPINB1, SPINT2 | ADRB3 4260/4885ADRA2B 4158/4885ADRA2C 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.